https://www.selleckchem.com/pr....oducts/Nafamostat-me
4 RM than SR group (all p 0.05). There was no significant difference in adverse events (12.5% vs 10%, p = 0.812) and length of postoperative hospital stay (8.3 vs 8.2days, p = 0.945). During a long-term follow-up of mean 37.4months (range 6-140months), no residue, recurrence or metastasis was observed in both groups. Compared with SR, ER has the similar safety and efficacy in the management of GSs, but contributes to a shorter operation time and lower medical costs. ER may be considered as the first-line treatment, es
Like
Comment
Share
